Opportunity Information: Apply for PAR 12 087
Apply for PAR 12 087
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "HIV Vaccine Research and Design (HIVRAD) Program (P01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Apr 8, 2014 and posted on Jan 31, 2012.
- Applicants must submit their applications by Apr 8, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Private institutions of higher education Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public housing authorities/Indian housing authorities County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The HIV Vaccine Research and Design (HIVRAD) Program (P01) (Funding Opportunity Number PAR-12-087) was a National Institutes of Health (NIH) discretionary grant opportunity aimed at accelerating discovery-stage research for preventive (prophylactic) HIV/AIDS vaccines. The program was built around the NIH P01 mechanism, which is designed to fund multi-project, team-based efforts rather than single-lab projects. In practice, this meant applicants were expected to assemble a coordinated set of interrelated research components that work together to answer major scientific questions that are difficult to tackle through isolated studies. The overall emphasis was on collaborative, multidisciplinary vaccine discovery research, bringing together expertise such as immunology, virology, structural biology, computational biology, protein engineering, vaccinology, and animal model research to move vaccine concepts forward in a cohesive way.
Scientifically, the opportunity focused on important, clearly defined problems relevant to AIDS prophylactic vaccine discovery. The intent was not simply to fund incremental work, but to support integrated projects that could generate new vaccine concepts, refine immunogen designs, and deepen understanding of protective immune responses. A notable feature of the description is that extensive modeling of vaccine concepts in non-human primates could be included, signaling that the program recognized the value of primate studies for evaluating immunogenicity, immune mechanisms, and protection-related endpoints where appropriate. While the announcement language is brief in the summary provided, the stated scope implies an interest in taking promising ideas beyond early in vitro work into more rigorous preclinical testing, especially when such testing is essential to validate a vaccine approach or to compare candidate strategies within a unified research plan.
From an administrative and funding standpoint, this was categorized under Health as the funding activity area and aligned with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The estimated total funding amount listed for the opportunity was $5,000,000, and there was no cost sharing or matching requirement, which is typical for many NIH research grants. The opportunity was originally posted on January 31, 2012, with an original closing date of June 13, 2014. The record shows a current closing date of April 8, 2014, a creation date of April 8, 2014, and an archive date of May 8, 2014, indicating the announcement is no longer active and has been archived.
Eligibility for PAR-12-087 was broad and inclusive, reflecting NIH’s typical approach to supporting biomedical research across sectors and institution types. Eligible applicants included public and private institutions of higher education, nonprofits (including 501(c)(3) organizations and other nonprofit entities), for-profit organizations (other than small businesses), small businesses, and multiple levels of government such as state, county, city/township, special district, and certain housing authorities. The eligibility language also explicitly encompassed a wide range of special categories and mission-driven institutions, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, among others. Importantly, non-U.S. entities were eligible to apply, non-U.S. components of U.S. organizations were eligible, and foreign components (as defined under the NIH Grants Policy Statement) were allowed. This international eligibility aligns with the global nature of HIV research and the need for broad scientific participation.
For applicants and interested parties seeking the original full announcement, NIH provided an official link to the archived funding notice on the NIH Grants Guide website (http://grants.nih.gov/grants/guide/pa-files/PAR-12-087.html). For technical issues accessing or linking to the announcement, the contact provided was the NIH Office of Extramural Research (OER) Webmaster via FBOWebmaster@OD.NIH.GOV. Overall, the HIVRAD P01 program was structured to fund coordinated, high-impact consortia-like projects focused on the discovery and design challenges that still stand between HIV biology and a broadly effective preventive vaccine, with room to incorporate substantial non-human primate work when that level of modeling was scientifically justified.
Frequently Asked Questions (FAQs): HIV Vaccine Research and Design (HIVRAD) Program (P01) - PAR-12-087
What is the HIV Vaccine Research and Design (HIVRAD) Program (P01), PAR-12-087?
The HIV Vaccine Research and Design (HIVRAD) Program (P01) (Funding Opportunity Number PAR-12-087) was a National Institutes of Health (NIH) discretionary grant opportunity focused on accelerating discovery-stage research for preventive (prophylactic) HIV/AIDS vaccines. It emphasized coordinated, collaborative research aimed at advancing vaccine concepts and immunogen design and improving understanding of protective immune responses.
What NIH grant mechanism did this opportunity use?
This opportunity used the NIH P01 mechanism. The P01 mechanism is designed for multi-project, team-based efforts rather than single-lab projects, with interrelated components that work together to address major scientific questions.
What type of research was this funding opportunity intended to support?
It was intended to support integrated, collaborative, multidisciplinary vaccine discovery research aimed at clearly defined problems relevant to prophylactic HIV vaccine discovery. The intent was to enable research that could generate new vaccine concepts, refine immunogen designs, and deepen understanding of protective immune responses.
Was this opportunity focused on preventive (prophylactic) or therapeutic HIV vaccines?
It was aimed at preventive (prophylactic) HIV/AIDS vaccines.
What does it mean that the program emphasized "multi-project" and "team-based" work?
It meant applicants were expected to propose a coordinated set of interrelated research components (projects) that collectively address major scientific questions that are difficult to tackle through isolated studies. The overall program emphasis was on cohesive, integrated research rather than incremental or disconnected efforts.
What scientific disciplines or expertise areas were highlighted as relevant?
The program description highlighted multidisciplinary collaboration and referenced expertise such as immunology, virology, structural biology, computational biology, protein engineering, vaccinology, and animal model research as examples of the kinds of expertise that could be brought together to move vaccine concepts forward.
Did the opportunity allow or encourage non-human primate studies?
Yes. The description notes that extensive modeling of vaccine concepts in non-human primates could be included, recognizing the value of primate studies for evaluating immunogenicity, immune mechanisms, and protection-related endpoints when appropriate to validate or compare vaccine approaches within an integrated research plan.
Was the program intended to fund incremental work?
No. The intent was not simply to fund incremental work, but to support integrated projects capable of generating new vaccine concepts, refining immunogen designs, and deepening understanding of protective immune responses.
What was the funding activity area for this opportunity?
The funding activity area was categorized under Health.
Which CFDA numbers were associated with PAR-12-087?
The opportunity aligned with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
What was the estimated total funding amount listed for the opportunity?
The estimated total funding amount listed was $5,000,000.
Was cost sharing or matching required?
No. The opportunity stated that there was no cost sharing or matching requirement.
When was the opportunity originally posted?
The opportunity was originally posted on January 31, 2012.
What were the closing dates shown for the opportunity?
The record shows an original closing date of June 13, 2014. It also shows a current closing date of April 8, 2014.
Is PAR-12-087 still an active funding opportunity?
No. The record indicates the announcement is no longer active and has been archived (archive date shown as May 8, 2014).
What dates indicate that the opportunity has been archived?
The record shows a creation date of April 8, 2014 and an archive date of May 8, 2014, indicating it is archived and no longer active.
Who was eligible to apply?
Eligibility was broad. Eligible applicants included public and private institutions of higher education, nonprofits (including 501(c)(3) organizations and other nonprofit entities), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (such as state, county, city/township, special district, and certain housing authorities).
Were mission-driven or special categories of institutions explicitly included?
Yes. The eligibility language explicitly included a wide range of institution types and categories, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, among others.
Were non-U.S. organizations eligible to apply?
Yes. Non-U.S. entities were eligible to apply.
Could non-U.S. components of U.S. organizations participate?
Yes. Non-U.S. components of U.S. organizations were eligible.
Were foreign components allowed under this opportunity?
Yes. Foreign components (as defined under the NIH Grants Policy Statement) were allowed.
Where can applicants find the original full announcement?
The original full announcement was available on the NIH Grants Guide website at: http://grants.nih.gov/grants/guide/pa-files/PAR-12-087.html
Who was the contact for technical issues accessing or linking to the announcement?
The contact provided for technical issues was the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What was the overarching goal of the HIVRAD P01 program?
The overarching goal was to fund coordinated, high-impact, consortia-like efforts focused on discovery and design challenges in prophylactic HIV vaccine research, enabling integrated progress from vaccine concepts and immunogen design toward deeper understanding of protective immune responses, with room for substantial non-human primate modeling when scientifically justified.
Browse more opportunities from the same category: Health
Next opportunity: Water Conservation Field Services Program
Previous opportunity: Americans With Disabilities Act (ADA) National Network Collaborative Research Project CFDA Number 84.133A 8
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 12 087
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 12 087) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strengthening of the National External Quality Assessment (EQA) Program through Establishment and Implementation of an Efficient Distribution and Analysis of Proficiency Materials for Human Immunodeficiency Virus (HIV), Tuberculosis, and Opportunisti Apply for CDC RFA GH12 1234 Funding Number: CDC RFA GH12 1234 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Partnerships for Development of Vaccine Technologies (R01) Apply for RFA AI 12 014 Funding Number: RFA AI 12 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Resource Access for the Bridging Interventional Development Gaps Program (X01) Apply for PAR 12 092 Funding Number: PAR 12 092 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NU HITES Apply for RFA 617 12 000005 Funding Number: RFA 617 12 000005 Agency: Uganda USAID Kampala Category: Health Funding Amount: $50,000,000 |
| Strengthening Systems, Capacity, and Data Collection with a Focus on Strategic Information in South Sudan under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1256 Funding Number: CDC RFA GH12 1256 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Engaging Local Indigenous Organizations in Improving Quality and Efficiency of HIV Care and Treatment Services in Ukraine under the Presidents Emergency Plan for HIV/AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1227 Funding Number: CDC RFA GH12 1227 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $700,000 |
| Establishment of an expanded Caribbean HIV/AIDS monitoring and evaluation technical assistance unit within the Caribbean Health Research Council (CHRC) under the Presidents Emergency Plan for AIDS Relief (PEPFAR Apply for CDC RFA GH12 1205 Funding Number: CDC RFA GH12 1205 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Planning Grant The Money Follows the Person Rebalancing Demonstration Program Apply for CMS 1LI 12 001 Funding Number: CMS 1LI 12 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $200,000 |
| Expanding Participation of People with Disabilities in USAID Activities andStrengthen the Capacities of Disabled Peoples Organizations (DPOs) Apply for RFA 114 12 000002 Funding Number: RFA 114 12 000002 Agency: Georgia USAID Tbilisi Category: Health Funding Amount: $600,000 |
| Implementation of a Program to Build the Institutional Apply for CDC RFA GH12 1243 Funding Number: CDC RFA GH12 1243 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,130,000 |
| Modeling Social Behavior (R01) Apply for RFA GM 13 006 Funding Number: RFA GM 13 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grand Challenges in Global Mental Health Integrating Mental Health into Chronic Disease Care Provision in Low and Middle Income Countries (R01) Apply for RFA MH 13 040 Funding Number: RFA MH 13 040 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Increasing Human Resources for Health and Epidemiological Capacity in the Republic of Guyana through a University Training Program under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1208 Funding Number: CDC RFA GH12 1208 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $440,000 |
| Sober Truth on Preventing Underage Drinking Act Grants Apply for SP 12 003 Funding Number: SP 12 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $50,000 |
| Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1250 Funding Number: CDC RFA GH12 1250 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $8,000,000 |
| Ancillary Studies in PREDICT HD (U01) Apply for PAR 12 097 Funding Number: PAR 12 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ancillary Domain Validation Patient Reported Outcomes Measurement Information System (PROMIS) Studies (R01) Apply for RFA AR 12 007 Funding Number: RFA AR 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| National Forum for State and Territorial Chief Executives Apply for HRSA 12 152 Funding Number: HRSA 12 152 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Reduce the Incidence and Mitigate the Impact of HIV/AIDS in Mali under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1231 Funding Number: CDC RFA GH12 1231 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Technical Assistance to The Ministry of Health (MOH) for HIV Services and Program Transition in Zambezia Province of the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH12 1224 Funding Number: CDC RFA GH12 1224 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $25,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 12 087", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.